DCN and colorectal carcinoma: We found that CRCs with activating mutations in the KRAS gene showed much larger underexpression of the DCN gene in comparison to normal tissue than CRCs without mutations in KRAS. In the Fearon and Vogelstein model, activating KRAS mutations are one of the first genomic events leading to the development of CRC.